Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CODOXY vs DELSYM
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Oxycodone is a full opioid agonist with relative selectivity for the mu-opioid receptor, although it can bind to other opioid receptors at higher doses. The principal therapeutic action of oxycodone is analgesia. Like all full opioid agonists, there is no ceiling effect for analgesia. Oxycodone is combined with aspirin to provide additive analgesic effects.
Dextromethorphan is a non-competitive NMDA receptor antagonist and sigma-1 receptor agonist, which suppresses cough by elevating the threshold for coughing in the medullary cough center.
Management of moderate to moderately severe pain where the use of an opioid analgesic is appropriate
Symptomatic relief of cough caused by minor throat and bronchial irritation
1-2 capsules orally every 4-6 hours as needed for pain, not to exceed 8 capsules per day. Each capsule contains 5 mg hydrocodone bitartrate and 325 mg acetaminophen.
60 mg orally every 12 hours (extended-release suspension).
Terminal half-life is 3.5 hours in patients with normal renal function; extends to 5-8 hours in moderate renal impairment.
Terminal elimination half-life of dextromethorphan is approximately 11 hours (range 9-14 hours) in extensive metabolizers; in poor metabolizers (CYP2D6 deficiency), half-life can exceed 24 hours, leading to accumulation.
Oxycodone is metabolized by CYP3A4 and CYP2D6. N-demethylation to noroxycodone (via CYP3A4) is the primary metabolic pathway. CYP2D6-mediated O-demethylation to oxymorphone is a minor pathway but produces a more potent metabolite.
Metabolized primarily by CYP2D6 to dextrorphan, an active metabolite; also undergoes O-demethylation and N-demethylation.
Renal excretion of unchanged drug accounts for approximately 70% of elimination; biliary/fecal excretion accounts for 30%.
Renal excretion of unchanged drug and metabolites, primarily dextrorphan glucuronide; <5% excreted unchanged in urine. Biliary/fecal elimination is negligible.
Approximately 92% bound to albumin.
~45-50% bound to plasma albumin; main binding protein is albumin.
2.4 L/kg; indicates extensive tissue distribution.
5-6 L/kg, indicating extensive tissue distribution.
Oral: 60-70% due to first-pass metabolism.
Oral: ~10-25% due to extensive first-pass metabolism (CYP2D6 and CYP3A4); bioavailability is higher in poor metabolizers.
For GFR 30-50 m L/min: administer every 8 hours. For GFR 10-29 m L/min: administer every 12 hours. For GFR <10 m L/min: use not recommended.
No dose adjustment recommended for mild-to-moderate renal impairment; safety in severe renal impairment not established.
Child-Pugh Class A: no adjustment. Child-Pugh Class B: reduce dose by 50% and extend interval to every 8 hours. Child-Pugh Class C: contraindicated.
No dose adjustment recommended for mild-to-moderate hepatic impairment; safety in severe hepatic impairment not established.
For children ≥2 years: 0.1-0.2 mg/kg hydrocodone component every 4-6 hours as needed, maximum 6 doses per day. Use weight-based dosing; do not exceed acetaminophen 75 mg/kg/day.
Children 6-11 years: 30 mg orally every 12 hours. Children 12 years and older: 60 mg orally every 12 hours. Do not exceed 60 mg in 24 hours for ages 6-11 or 120 mg for ages 12+.
Initiate at lowest effective dose (e.g., 1 capsule every 6 hours) due to increased risk of respiratory depression and falls. Titrate cautiously. Maximum 6 capsules per day.
Start at low end of dosing range; monitor for anticholinergic effects and sedation. No specific dose adjustment in elderly but caution due to increased sensitivity.
Addiction, abuse, and misuse; life-threatening respiratory depression; accidental ingestion; neonatal opioid withdrawal syndrome; risks from concomitant use with benzodiazepines or other CNS depressants; and interactions with drugs affecting cytochrome P450 isoenzymes.
None
Addiction, abuse, and misuse; life-threatening respiratory depression; accidental ingestion; neonatal opioid withdrawal syndrome; risks from concomitant use with benzodiazepines or other CNS depressants; severe hypotension; gastrointestinal obstruction; seizures; serotonin syndrome; adrenal insufficiency; and androgen deficiency.
Do not use in children under 4 years of age,Avoid use with MAO inhibitors or for 2 weeks after stopping,Chronic use may lead to dependence and abuse,Caution in patients with respiratory depression, asthma, or chronic obstructive pulmonary disease
Significant respiratory depression; acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment; known or suspected gastrointestinal obstruction, including paralytic ileus; hypersensitivity to oxycodone, aspirin, or any component of the formulation.
Hypersensitivity to dextromethorphan or any component,Use with or within 14 days of MAO inhibitors,Use in patients with respiratory depression or severe asthma
Avoid alcohol and grapefruit juice. Alcohol potentiates CNS depression. Grapefruit juice may increase codeine metabolism via CYP3A4, leading to variable effects. No significant food restrictions otherwise; take with food if GI upset occurs.
No significant food interactions. Avoid grapefruit juice as it may increase dextromethorphan levels. Take with or without food.
No human data; animal studies not available. Avoid during pregnancy, especially first trimester, due to potential oxycodone-induced neural tube defects.
Category D (positive evidence of human fetal risk): First trimester exposure associated with rare reports of congenital malformations including cardiac defects and oral clefts based on observational studies. Second and third trimester use may cause fetal respiratory depression, bradycardia, and neonatal adaptation syndrome with prolonged use near term. Risks increase with higher doses and chronic use.
Oxycodone is excreted into breast milk; M/P ratio ~3.6:1. Risk of infant sedation and respiratory depression. Contraindicated during breastfeeding.
Excreted into breast milk in low concentrations (M/P ratio 0.1–0.4). Considered compatible with breastfeeding by American Academy of Pediatrics; however, monitor infant for drowsiness, respiratory depression, and poor feeding. Avoid if infant is premature or has respiratory compromise. Use shortest duration possible.
No established dose adjustments; increased clearance in pregnancy may require higher doses for analgesia, but use is contraindicated.
No pharmacokinetic studies show significant changes in dextromethorphan clearance during pregnancy. Therefore, no empiric dose adjustment is recommended. However, because of increased plasma volume and renal blood flow in pregnancy, the duration of action may be shorter, requiring more frequent dosing if clinically indicated. Use lowest effective dose for shortest duration.
CODOXY is a fixed-dose combination of codeine (opioid) and doxylamine (antihistamine). Use lowest effective dose for shortest duration due to opioid dependence and respiratory depression risk. Avoid in children <12 years for post-tonsillectomy pain and in those <18 with respiratory compromise. Monitor for CNS depression, especially with alcohol. Doxylamine adds anticholinergic effects (constipation, dry mouth, urinary retention). Caution in elderly, renal impairment, and breastfeeding.
DELSYM (dextromethorphan polistirex) is a sustained-release formulation providing up to 12 hours of cough suppression. Do not crush or chew capsules; swallow whole. Avoid use in patients with asthma, COPD, or respiratory insufficiency due to risk of respiratory depression. Contraindicated with MAOIs and within 14 days of MAOI use due to serotonin syndrome risk. Not recommended for chronic cough or cough associated with excessive secretions. Use caution in patients with G6PD deficiency (rare hemolysis risk).
Take exactly as prescribed; do not increase dose or frequency without consulting your doctor.,This medication may cause drowsiness, dizziness, or blurred vision; avoid driving or operating machinery until you know how it affects you.,Avoid alcohol and other sedatives (e.g., benzodiazepines, sleep aids) as they increase risk of severe drowsiness and breathing problems.,Do not use with other products containing codeine or antihistamines (including cough/cold medicines).,Store securely away from children; misuse can cause addiction, overdose, or death.,If you are pregnant, plan to become pregnant, or are breastfeeding, inform your healthcare provider before use.,Common side effects: constipation, dry mouth, nausea. Increase fluid intake and fiber to prevent constipation.,Seek emergency help if you experience slow or shallow breathing, confusion, or fainting.
Take DELSYM only as directed for temporary cough relief.,Swallow capsules whole; do not crush, chew, or dissolve.,Do not exceed recommended dose or use for more than 7 days unless directed by a doctor.,Avoid alcohol while taking this medication.,Do not use if you are taking or have taken a monoamine oxidase inhibitor (MAOI) within the last 14 days.,Seek medical attention if cough persists, comes with fever, rash, or headache, or if you experience signs of serotonin syndrome (agitation, hallucinations, rapid heart rate, fever, muscle stiffness).,Keep out of reach of children; accidental overdose may cause death.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CODOXY vs DELSYM, answered by our medical review team.
CODOXY is a Antitussive Combination that works by Oxycodone is a full opioid agonist with relative selectivity for the mu-opioid receptor, although it can bind to other opioid receptors at higher doses. The principal therapeutic action of oxycodone is analgesia. Like all full opioid agonists, there is no ceiling effect for analgesia. Oxycodone is combined with aspirin to provide additive analgesic effects.. DELSYM is a Antitussive that works by Dextromethorphan is a non-competitive NMDA receptor antagonist and sigma-1 receptor agonist, which suppresses cough by elevating the threshold for coughing in the medullary cough center.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CODOXY and DELSYM depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CODOXY is: 1-2 capsules orally every 4-6 hours as needed for pain, not to exceed 8 capsules per day. Each capsule contains 5 mg hydrocodone bitartrate and 325 mg acetaminophen.. The standard adult dose of DELSYM is: 60 mg orally every 12 hours (extended-release suspension).. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CODOXY and DELSYM in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CODOXY is classified as Category C. No human data; animal studies not available. Avoid during pregnancy, especially first trimester, due to potential oxycodone-induced neural tube defects.. DELSYM is classified as Category C. Category D (positive evidence of human fetal risk): First trimester exposure associated with rare reports of congenital malformations including cardiac defects and oral clefts base. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.